Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men

Abstract

Background:

Reliable biomarkers of androgen activity in humans are lacking. The aim of this study was, therefore, to identify new protein markers of biological androgen activity and test their predictive value in relation to low vs. normal testosterone values and some androgen deficiency linked pathologies.

Methods:

Blood samples from 30 healthy GnRH-antagonist treated males were collected at three time points: a) before GnRH antagonist administration; b) 3 weeks later, just before testosterone undecanoate injection, and c) after additional 2 weeks. Subsequently they were analysed by mass spectrometry to identify potential protein biomarkers of testosterone activity. Levels of proteins most significantly associated with testosterone fluctuations were further tested in a cohort of 75 hypo- and eugonadal males suffering from infertility. Associations between levels of those markers and cardio-metabolic parameters, bone mineral density as well as androgen receptor CAG repeat lengths, were explored.

Results:

Using ROC analysis, 4-hydroxyphenylpyruvate dioxygenase (4HPPD), insulin-like growth factor-binding protein 6 (IGFBP6) and fructose-bisphosphate aldolase (ALDOB), as well as a Multi Marker Algorithm, based on levels of 4HPPD and IGFBP6, were shown to be best predictors of low (< 8 nmol/L) vs. normal (> 12 nmol/L) testosterone. They were also more strongly associated with metabolic syndrome and diabetes than testosterone levels. Levels of ALDOB and 4HPPD levels also showed association with AR CAG-repeat lengths.

Conclusions:

We identified potential new protein biomarkers of testosterone action. Further investigations to elucidate their clinical potential are warranted.

Funding:

The work was supported by ReproUnion 2.0 (grant no 20201846), which is funded by the Interreg V EU program.

Data availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (60) partner repository with the dataset identifier PXD024448.Supplementary tables (datasets):https://doi.org/10.6084/m9.figshare.14875431Source data of the Figures can be found on:https://doi.org/10.6084/m9.figshare.14875431Supplementary Figure S1 (Figure 2-figure supplement 1):https://doi.org/10.6084/m9.figshare.14876562

The following data sets were generated

Article and author information

Author details

  1. Aleksander Giwercman

    Department of Translational Medicine, Lund University, Malmo, Sweden
    For correspondence
    aleksander.giwercman@med.lu.se
    Competing interests
    Aleksander Giwercman, received consulting fees from Besins Healthcare. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5816-0785
  2. K Barbara Sahlin

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  3. Indira Pla Parada

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  4. Krzysztof Pawlowski

    Department of Experimental Design and Bioinformatics, Warsaw University of Life Sciences, Warszawa, Poland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5367-0935
  5. Carl Fehninger

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0922-7749
  6. Yvonne Lundberg Giwercman

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.
  7. Irene Leijonhufvud

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.
  8. Roger Appelqvist

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  9. György Marko-Varga

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  10. Aniel Sanchez

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  11. Johan Malm

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.

Funding

ReproUnion (20201846)

  • Aleksander Giwercman

Swedish Governmental Fund for Clinical Research

  • Aleksander Giwercman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: All subjects were enrolled with informed written consent. The two studies from which they were recruited were approved by the Swedish Ethical Review Authority (Approval number: DNR 2014/311, date of approval 8 May 2014; DNR 2011/1, date of approval 11 January 2011).

Reviewing Editor

  1. Nima Sharifi, Cleveland Clinic, United States

Version history

  1. Received: October 12, 2021
  2. Preprint posted: November 14, 2021 (view preprint)
  3. Accepted: February 28, 2022
  4. Accepted Manuscript published: March 1, 2022 (version 1)
  5. Version of Record published: April 8, 2022 (version 2)

Copyright

© 2022, Giwercman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 848
    Page views
  • 146
    Downloads
  • 3
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Aleksander Giwercman
  2. K Barbara Sahlin
  3. Indira Pla Parada
  4. Krzysztof Pawlowski
  5. Carl Fehninger
  6. Yvonne Lundberg Giwercman
  7. Irene Leijonhufvud
  8. Roger Appelqvist
  9. György Marko-Varga
  10. Aniel Sanchez
  11. Johan Malm
(2022)
Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men
eLife 11:e74638.
https://doi.org/10.7554/eLife.74638

Share this article

https://doi.org/10.7554/eLife.74638

Further reading

    1. Medicine
    Shengjie Li, Jun Ren ... Wenjun Cao
    Research Article

    Background:

    Primary angle closure glaucoma (PACG) is the leading cause of irreversible blindness in Asia, and no reliable, effective diagnostic, and predictive biomarkers are used in clinical routines. A growing body of evidence shows metabolic alterations in patients with glaucoma. We aimed to develop and validate potential metabolite biomarkers to diagnose and predict the visual field progression of PACG.

    Methods:

    Here, we used a five-phase (discovery phase, validation phase 1, validation phase 2, supplementary phase, and cohort phase) multicenter (EENT hospital, Shanghai Xuhui Central Hospital), cross-sectional, prospective cohort study designed to perform widely targeted metabolomics and chemiluminescence immunoassay to determine candidate biomarkers. Five machine learning (random forest, support vector machine, lasso, K-nearest neighbor, and GaussianNaive Bayes [NB]) approaches were used to identify an optimal algorithm. The discrimination ability was evaluated using the area under the receiver operating characteristic curve (AUC). Calibration was assessed by Hosmer-Lemeshow tests and calibration plots.

    Results:

    Studied serum samples were collected from 616 participants, and 1464 metabolites were identified. Machine learning algorithm determines that androstenedione exhibited excellent discrimination and acceptable calibration in discriminating PACG across the discovery phase (discovery set 1, AUCs=1.0 [95% CI, 1.00–1.00]; discovery set 2, AUCs = 0.85 [95% CI, 0.80–0.90]) and validation phases (internal validation, AUCs = 0.86 [95% CI, 0.81–0.91]; external validation, AUCs = 0.87 [95% CI, 0.80–0.95]). Androstenedione also exhibited a higher AUC (0.92–0.98) to discriminate the severity of PACG. In the supplemental phase, serum androstenedione levels were consistent with those in aqueous humor (r=0.82, p=0.038) and significantly (p=0.021) decreased after treatment. Further, cohort phase demonstrates that higher baseline androstenedione levels (hazard ratio = 2.71 [95% CI: 1.199–6.104], p=0.017) were associated with faster visual field progression.

    Conclusions:

    Our study identifies serum androstenedione as a potential biomarker for diagnosing PACG and indicating visual field progression.

    Funding:

    This work was supported by Youth Medical Talents – Clinical Laboratory Practitioner Program (2022-65), the National Natural Science Foundation of China (82302582), Shanghai Municipal Health Commission Project (20224Y0317), and Higher Education Industry-Academic-Research Innovation Fund of China (2023JQ006).

    1. Medicine
    Swee Sen Kwek, Eng Eong Ooi
    Insight

    Understanding the kinetics of dengue viruses in the bloodstream can provide insights into the clinical outcomes of the disease.